John Lechleiter


John Lechleiter News

  • Drugmakers in Deal Frenzy Seek to Be First, Best or Gone

    Do a few things, and do them well.

  • Novartis, Glaxo Do Big Deals Without the Big

    It’s not just size that counts.

  • Lilly CEO Lechleiter Returns Following May Heart Surgery

    Eli Lilly & Co. Chairman and Chief Executive Officer John Lechleiter returned to his positions full-time following surgery to repair a heart defect in May.

  • Lilly CEO Lechleiter Has Surgery to Repair Heart

    Eli Lilly & Co. Chief Executive Officer John Lechleiter underwent a scheduled surgery yesterday for a heart defect and the repair to the aorta is functioning as intended, the drugmaker said.

  • Lilly CEO Urges Extension of Research Tax Credit (Transcript)

    Eli Lilly & Co. Chief Executive Officer John Lechleiter said during a panel discussion in Washington that U.S. lawmakers should renew the research-and- development tax credit to make it easier for companies to compete globally. The Oct. 5 event, sponsored by Harvard University and the Business Roundtable and hosted by Bloomberg News in Washington, centered on ways to spur innovation.

  • Patent Office Must Control Funds, MIT Leader Says (Transcript)

    Massachusetts Institute of Technology President Susan Hockfield said during a panel discussion in Washington that Congress must keep its pledge to let U.S. Patent and Trademark Office, or PTO, have control over all the fees it collects to promote innovation and spur job creation. The Oct. 5 event, sponsored by Harvard University and the Business Roundtable and hosted by Bloomberg News, centered on ways to spur innovation.

  • Eli Lilly to Focus on Cancer, Diabetes in China, CEO Says

    Eli Lilly & Co. will introduce more than a dozen products in China, including drugs for diabetes and cancer, in the next five years to help maintain sales growth, Chief Executive Officer John Lechleiter said.

  • Eli Lilly Raises 2013 Profit Forecast After Cost Cuts

    Eli Lilly & Co., the maker of the antidepressant Cymbalta and diabetes treatment Humalog, raised its full-year forecast after second-quarter sales grew faster than expected and cost-cutting programs took effect.

  • Cantor Calls for Action on Skilled-Worker Exodus (Transcript)

    U.S. House Majority Leader Eric Cantor, a Virginia Republican, told a gathering of chief executive officers and university leaders that the U.S. must grant visas to skilled workers from overseas more quickly to halt an “exodus” of “foreign nationals in this country who come here” to attend universities “and then find it too difficult to stay here.” The Oct. 5 event at Bloomberg News’ Washington bureau was sponsored by Harvard University and the Business Roundtable.

  • Eli Lilly Chief Says China Too Slow in Approving New Drugs

    China takes eight years longer on average to approve drugs than other major countries and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly & Co. Chief Executive Officer John Lechleiter said.

John Lechleiter Photos

Advertisement
Sponsored Links
Advertisement
Curation software by Lingospot